Correspondence 0001104659-26-029722 from Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc.
Date: March 17, 2026 · CIK: 0001781983 · Accession: 0001104659-26-029722
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293609
Letter
APREA THERAPEUTICS, INC.
3805 Old Easton Road
Doylestown, PA 18902
March 17, 2026
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Alan Campbell
Re: Aprea Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-293609
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Aprea Therapeutics, Inc. (the " Registrant ") hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-293609), so that it may become effective at 5:00 p.m. Eastern Time on March 19, 2026, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Please call Patrick O'Malley, Esq. of DLA Piper LLP (US), counsel to the Company, at (206) 839-4831, with any comments or questions regarding the Registration Statement.
Very truly yours,
APREA THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm APREA THERAPEUTICS, INC. 3805 Old Easton Road Doylestown, PA 18902 March 17, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: Aprea Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-293609 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Aprea Therapeutics, Inc. (the " Registrant ") hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-293609), so that it may become effective at 5:00 p.m. Eastern Time on March 19, 2026, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff. The cooperation of the staff in meeting the timetable described above is very much appreciated. Please call Patrick O'Malley, Esq. of DLA Piper LLP (US), counsel to the Company, at (206) 839-4831, with any comments or questions regarding the Registration Statement. Very truly yours, APREA THERAPEUTICS, INC. By: /s/ John Hamill Name: John Hamill Title: Senior Vice President and Chief Financial Officer cc: Fahd Riaz, Esq., DLA Piper LLP (US) Dylan Caplan, Esq., DLA Piper LLP (US)